Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 10/20 | 0.77 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | TEK | Q02763 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 4/20 | 0.47 |
| ▸ | CCND1 | P24385 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | CCND2 | P30279 | 1/20 | 0.47 |
| ▸ | CCND3 | P30281 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | WEE1 | P30291 | 3/20 | 0.46 |
| ▸ | PLK1 | P53350 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955963 | 0.85 | TNK2 (0.70) | TNK2KDRLCKJAK3TEK | |
| SCHEMBL30338621 | 0.82 | TNK2 (1.00) | TNK2KDRLCKJAK3TEK | |
| SCHEMBL2953363 | 0.78 | TNK2 (0.64) | TNK2KDRLCKJAK3TEK | |
| SCHEMBL30338625 | 0.77 | TNK2 (1.00) | TNK2KDRLCKJAK3TEK | |
| SCHEMBL2958052 | 0.74 | TNK2 (0.84) | TNK2KDRLCKJAK3TEK | |
| SCHEMBL30338409 | 0.74 | TNK2 (0.84) | TNK2KDRLCKJAK3TEK | |
| SCHEMBL2952193 | 0.73 | TNK2 (0.64) | TNK2KDRLCKJAK3TEK | |
| SCHEMBL12064950 | 0.71 | CDK4 (0.62) | KDRFLT3CDK4CCND1EGFR | |
| SCHEMBL30620425 | 0.71 | CDK4 (0.67) | FLT3CDK4CCND1EGFRCCND3 | |
| SCHEMBL270386 | 0.71 | CDK4 (0.67) | FLT3CDK4CCND1EGFRCCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763624-B2 | Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors | AMGEN INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | LCK, MAP4K5, TPMT | TNK2 113/4885KDR 1313/4885LCK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.